Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2011 March;53(1) > Panminerva Medica 2011 March;53(1):37-49

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

PANMINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,698


eTOC

 

  STENT FOR LIFE


Panminerva Medica 2011 March;53(1):37-49

Copyright © 2011 EDIZIONI MINERVA MEDICA

language: English

Assessing drug elution technologies in the superficial femoral artery

Owens C. D., Gasper W. J., Conte M. S.

Division of Vascular and Endovascular Surgery, University of California San Francisco, San Francisco, CA, USA


PDF  


The endovascular management of symptomatic atherosclerotic superficial femoral artery (SFA) disease is challenging and requires consideration of unique anatomical, hemodynamic, and biomechanical factors. The current armamentarium of balloon catheters and flexible nitinol bare metal stents have limited long-term efficacy due to intimal hyperplasia resulting in restenosis. Unfortunately, the remarkably low restenosis rates achieved with drug eluting stents placed in the coronary vasculature has not been replicated in the femoral artery. The reason for this is multifactorial including delivery platforms, drug and dosage selection and trial design flaws. Currently, however, there are several novel therapies and delivery platforms in the development pipeline that have exhibited biologic effectiveness in preclinical and early clinical trials. While these offer promise in improving outcomes following lower extremity intervention, caution is warranted until the safety of these new technologies can be ensured.

top of page

Publication History

Cite this article as

Corresponding author e-mail

christopher.owens@ucsfmedctr.org